Cargando…
COVID-19 in Pulmonary Artery Hypertension (PAH) Patients: Observations from a Large PAH Center in New York City
Information on outcomes of COVID-19 in pulmonary arterial hypertension (PAH) patients is limited to a few case series and surveys. Here, we describe our experience at a large Pulmonary Hypertension Center in New York City at the height of the pandemic. We performed a retrospective chart review of el...
Autores principales: | Sulica, Roxana, Cefali, Frank, Motschwiller, Caroline, Fenton, Rebecca, Barroso, Anabela, Sterman, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7829711/ https://www.ncbi.nlm.nih.gov/pubmed/33467533 http://dx.doi.org/10.3390/diagnostics11010128 |
Ejemplares similares
-
Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center
por: Sulica, Roxana, et al.
Publicado: (2015) -
Biodegradation of Mixed PAHs by PAH-Degrading Endophytic Bacteria
por: Zhu, Xuezhu, et al.
Publicado: (2016) -
Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
por: Steele, Peter, et al.
Publicado: (2010) -
PAH Exposure
por: Fowler, Paul A., et al.
Publicado: (2009) -
The accumulation of metals, PAHs and alkyl PAHs in the roots of Echinacea purpurea
por: Pretorius, Travers R., et al.
Publicado: (2018)